कंपनी का अवलोकन
Viridian Therapeutics, Inc. (VRDN) is a biotechnology entity dedicated to the discovery, development, and commercialization of therapeutic interventions for serious and rare diseases, with a specific focus on IGF-1R therapies designed to treat conditions such as thyroid eye disease (TED). The company operates within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself as a provider of differentiated humanized monoclonal antibodies like Veligrotrug that are administered intravenously. As of the latest reporting period, the firm maintains a market capitalization of $1.48B and employs a workforce of 252 individuals, generating total annual revenue of $70.85M over the trailing twelve-month period. These financial dimensions indicate that while the company possesses a substantial market valuation relative to its current revenue base, the valuation metrics suggest the market is pricing in significant future growth potential and commercial success from its pipeline assets rather than current operational profitability.
वित्तीय स्वास्थ्य
The company reported a revenue of $70.85M for the trailing twelve months, yet this top-line figure contrasts sharply with a net income of $-281,928,000 and an EBITDA of $-362,935,008. The substantial disparity between the positive revenue of $70.85M and the negative net income of $-281,928,000 reveals a cost structure where operating expenses, likely driven by research and development activities and commercialization efforts, vastly exceed current sales generation. Furthermore, the free cash flow stands at $-162,068,368, which indicates that the company is currently burning cash to fund its operations and pipeline advancement rather than generating liquidity from its core business activities. Analysis of the margin profile shows a Gross Margin of 0.0%, an Operating Margin of -95643.2%, and a Profit Margin of 0.0%, collectively indicating that the company is not yet profitable at the gross or operating level due to the high fixed costs associated with biotechnology development phases. Regarding balance sheet strength, the company holds $874.65M in cash against total debt of $52.59M, resulting in a debt-to-equity ratio of 7.28, which suggests a leveraged capital structure heavily reliant on equity financing or cash reserves rather than traditional debt servicing. The current ratio is recorded at 12.65, a metric that indicates an extremely high level of short-term liquidity and a robust ability to cover short-term obligations with current assets. Additionally, the Return on Equity is -49.2% and the Return on Assets is -27.7%, figures that reveal that management is currently generating negative returns on both shareholder capital and total assets, typical for early-stage development companies but requiring successful product commercialization to reverse.
मूल्यांकन आकलन
The valuation metrics for Viridian Therapeutics present a complex picture, with a Trailing P/E Ratio (TTM) listed as N/A due to the lack of earnings and a Forward P/E of -6.45, which implies that the market expects earnings to be negative in the near term or that the stock is priced based on future revenue milestones rather than current profitability. The Price to Book ratio is 2.50, suggesting that the market values the company at two and a half times its book value, which indicates a significant premium assigned to the intangible assets of its drug pipeline and future revenue potential despite current losses. Alternative valuation metrics such as the Price to Sales ratio of 20.87 and the EV/EBITDA of -2.17 further highlight that investors are pricing the stock based on revenue generation capacity and enterprise value relative to losses, rather than traditional earnings-based multiples. The stock's price action over the last year ranges between a low of $9.90 and a high of $34.29, meaning the current trading position fluctuates within a range that reflects high volatility typical of biotechnology equities. The Beta of 1.17 indicates that the stock exhibits price volatility that is 17% higher than the broader market, signifying that VRDN is more sensitive to market swings than the average large-cap stock.
Growth & Income
Viridian Therapeutics demonstrated a revenue growth rate of 83.3% year-over-year, while earnings growth is listed as N/A due to the absence of positive net income, implying that the company is prioritizing revenue expansion and pipeline progression over immediate profitability. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which confirms that the firm reinvests all available cash flow and generated revenue directly into research, development, and commercialization efforts rather than distributing income to shareholders. This lack of dividend distribution aligns with the strategic profile of a biotechnology firm that must allocate capital to advance its therapies through clinical trials and regulatory approval processes to achieve future commercial success. The overall growth and income profile is characterized by rapid revenue expansion supported by a robust cash reserve, though the absence of earnings growth and dividend income reflects the high-risk, high-reward nature of the biotechnology investment thesis.